

# Graves Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/GF60904B8402EN.html>

Date: November 2022

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: GF60904B8402EN

## Abstracts

Graves Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Drugs In Development, 2022, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graves Diseases (Hormonal Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Global Markets Direct Report Coverage

Graves Diseases - Overview

Graves Diseases - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Graves Diseases - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graves Diseases - Companies Involved in Therapeutics Development

advanceCor GmbH

AV7 Ltd

GSK plc

Omeros Corp

OSE Immunotherapeutics SA

Protheragen Inc

Virtici LLC

Worg Pharmaceuticals Hangzhou Co Ltd

Graves Diseases - Drug Profiles

belimumab - Drug Profile

Product Description

Mechanism Of Action

FR-104 - Drug Profile

Product Description

Mechanism Of Action

GPCR-targeted Project 001 - Drug Profile

Product Description

Mechanism Of Action

GPR174 - Drug Profile

Product Description

Mechanism Of Action

K-170 - Drug Profile

Product Description

Mechanism Of Action

## Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile

Product Description

Mechanism Of Action

VTCG-90 - Drug Profile

Product Description

Mechanism Of Action

WP-1302 - Drug Profile

Product Description

Mechanism Of Action

Graves Diseases - Dormant Projects

Graves Diseases - Product Development Milestones

Featured News & Press Releases

Jun 20, 2019: Apitope announces publication of data in international peer-reviewed journal thyroid on Graves' disease Therapy

Aug 14, 2018: Apitope Announces Publication of Graves' Disease Data in International Peer-Reviewed Journal, Endocrinology

Apr 16, 2018: Apitope Announces Positive Results with Novel Treatment for Graves Disease

Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease

Jun 19, 2014: Apitope Progresses Graves' Disease Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Graves Diseases, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Graves Diseases - Pipeline by advanceCor GmbH, 2022  
Graves Diseases - Pipeline by AV7 Ltd, 2022  
Graves Diseases - Pipeline by GSK plc, 2022  
Graves Diseases - Pipeline by Omeros Corp, 2022  
Graves Diseases - Pipeline by OSE Immunotherapeutics SA, 2022  
Graves Diseases - Pipeline by Protheragen Inc, 2022  
Graves Diseases - Pipeline by Virtici LLC, 2022  
Graves Diseases - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022  
Graves Diseases - Dormant Projects, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Graves Diseases, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022



## I would like to order

Product name: Graves Diseases Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/GF60904B8402EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF60904B8402EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

